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Background. Interventional Pain Management (IPM) is performed in multidisciplinary chronic pain clinics (MCPC), including
a range of invasive techniques to diagnose and treat chronic pain (CP) conditions. Current patterns of use of those techniques
in MCPC have not yet been reported. Objective. We aimed to describe quantitatively and qualitatively the use of IPM and other
therapeutic procedures performed on-site at four PortugueseMCPC.Methods. A prospective cohort study with one-year follow-up
was performed in adult patients. A structured case report form was systematically completed at baseline and six and 12 months.
Results. Among 808 patients referred to theMCPC, 17.2% had been prescribed IPM. Patients with IPMwere on average younger and
had longer CP duration and lower levels ofmaximumpain and pain interference/disability.The threemain diagnoses were low back
pain (𝑛 = 28), postoperative CP, and knee pain (𝑛 = 16 each). From 195 IPM prescribed, nerve blocks (𝑛 = 108), radiofrequency
(𝑛 = 31), and viscosupplementation (𝑛 = 22) were the most prevalent. Some IPM techniques were only available in few MCPC.
One MCPC did not provide IPM. Conclusions. IPM are seldom prescribed in Portuguese MCPC. Further studies on IPM safety
and effectiveness are necessary for clear understanding the role of these techniques in CP management.
1. Introduction
Chronic pain (CP) is a worldwide public health problem
that causes a substantial burden on healthcare systems and
society, taking into account its high prevalence, economic
costs, and the quality of life impairment of the patients and
their families. CP requires a multidisciplinary approach for
its adequate assessment and management [1–5]. For more
than twenty years, the International Association for the Study
of Pain (IASP) defined chronic CP as “pain that persists
beyond normal tissue healing time, which is assumed to be
3 months” [6]. Variations in the definition of CP between
and within countries, differences in standards of living and
healthcare resources, high prevalence of pain-generating
diseases, cultural background, and local traditions can help
explain the estimated CP prevalence ranging from 11% to 55%
[2, 7–9]. In a recent epidemiological study, CP prevalence in
Portugal was estimated at 37% [10]. CP of moderate to severe
intensity has been estimated to occur in 19% of European
adults and 40% of them reported inadequate management of
their pain [8, 11].
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CP is one of the most common reasons why people seek
medical care [1]. The economic impact of CP in the USA, in
2008, ranged from $560 to $635 billion USD [12]; in Portugal,
it was €4611.69 million (in 2010), corresponding to 2.71% of
the Portuguese annual gross domestic product, with 42.7%
direct and 57.3% indirect costs [2]. Indirect costs of CP are
mainly linked to work absenteeism with reduced levels of
productivity and increased risk of leaving the labor market
[13].
Ideally, supported by the most recent guidelines for the
CP management, these patients should have access to a mul-
tidisciplinary range of diagnostic and therapeutic modalities
appropriate to their clinical condition [14–17]. The primary
emphasis should be placed on pain management to improve
physical and social function and minimize the disability
[18–20]. Painmanagement includes pharmacological therapy,
psychological assessment and treatment, invasive techniques,
occupational therapy, and rehabilitation medicine [2, 15, 20–
25]. Interventional Pain Management (IPM) encompasses a
wide variety of techniques such as epidural injections [26–
29], nerve blocks [18, 21, 30], joint infiltrations [31, 32], spinal
cord stimulation [33, 34], botulinum toxin application [35–
37], and radiofrequency denervation [38, 39]. Recent data
suggests that some of the IPM techniques allow a superior
improvement in physical and functional status of CP patients
[18, 25, 26, 35, 38], as well as a reduction in associated
work absenteeism [18]. Other therapeutic procedures (OTP)
are also performed on-site at multidisciplinary chronic pain
clinics (MCPC), namely, acupuncture [40–46] and infusion
of parenteral drugs [47–49].
In Portugal, there is no available information regarding
patterns of prescription of IPM or OTP performed on-site at
MCPC. Therefore, as a part of a larger real-world outcomes
research prospective cohort study on CP patients followed
at MCPC, this study inquired about the utilization of those
techniques and procedures. We aimed at describing quanti-
tatively and qualitatively the patterns of prescription of IPM
and OTP performed on-site at MCPC in Portugal.
2. Methods
2.1. Selection and Description of Participants. Participants
were recruited at their first consultation in four MCPC from
the North of Portugal, in the context of a large real-world
outcomes research project. The eligible population included
adult patients (≥18 years old) with chronic noncancer pain
lasting more than 3 months (the standard IASP criteria
for CP [50]) or with cancer pain regardless of its dura-
tion. Patients with psychiatric and/or cognitive impairment,
unable to communicate verbally or not fluent in Portuguese
were excluded. Participants were followed for twelve months
and their clinical records were obtained at baseline and
six and 12 months. From all 1343 patients eligible, 808
patients were elected to be part of this study. From these, 139
patients had IPM at least once during the one-year follow-up
(Supplement 1 in Supplementary Material available online at
https://doi.org/10.1155/2017/8402413).
All participating patients were previously informed of the
study objectives and about the data selection and collection
procedures, and questions regarding the study, posed by the
patients, were properly answered by the research team. All
participating patients signed an informed consent form. The
study protocol was approved by institutional review boards,
ethics committees of the participating hospitals, and CNPD,
the Portuguese Data Protection Authority.
2.2. Instruments and Variables. A structured questionnaire
was used in baseline interviews. For the purpose of the
present study the following data were systematically col-
lected: demographic characteristics, clinical and pain char-
acteristics, and IPM and OTP performed on-site at MCPC
prescribed. The Brief Pain Inventory (BPI) [51] which is rec-
ommended by consensus groups in the area of measurement
and evaluation of pain [52] was used. This instrument was
constructed for measuring and evaluating pain in a multidi-
mensional perspective. It includes 15 items evaluating pain
presence, severity, location, functional interference, thera-
peutic strategies, and efficacy of pain management. It is easily
applicable, fast, and simple and with very good psychometric
properties [53–56]. For the present study, only two constructs
were assessed: pain severity and functional interference. Pain
severity scale entails four items, maximum, minimum, on
average, and at this moment, rated with a numerical scale
(0 [no pain] to 10 [the worst pain]) and categorized using
Serlin et al. classification [57]. The functional interference
scale consists of seven items with numerical rating scale (0
[no interference] to 10 [extreme interference]) that assess
pain interference in general activities, mood, mobility, work,
personal relationships, sleep, and pleasure to live.
In the descriptive analysis of the sample (all patients)
and subsamples (patients with and without IPM), we
defined the general characteristics, including sociodemo-
graphic (sex, age, educational level, and family support),
professional/occupational status, pain characteristics (dura-
tion, persistence pattern, location, severity, and interference),
general health, and clinical variables (International Statistical
Classification of Diseases and Related Health Problems-
(ICD-) 10 diagnostic classification). The persistence pattern
of pain was classified as continuous, pain present every
day/always, or discontinuous (recurrent [pain present once
to several times/week] and sporadic [pain present less than
once to several times/month]).
2.3. Statistical Analysis. Categorical variables were described
as absolute (𝑛) and relative (%) frequencies; continuous
variables were described using the median and interquar-
tile ranges considering the tested asymmetric (not normal)
distribution or mean and standard deviation otherwise.
We used the Chi-square test, or the Fisher’s exact test,
to test hypotheses for categorical variables. In the case of
continuous variables (with asymmetrical distribution) the
Mann–Whitney test was used. For all hypothesis tests a
significance level of 𝛼 = 0.05 was considered. The statistical
analysis was performed using the software SPSS v21.0.
3. Results
Table 1 shows the number of patients that were prescribed
IPM and/or OTP throughout the study. Considering IPM,
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Table 1: Number of patients that received a prescription of interventional pain management and other therapeutic procedures performed
on-site at multidisciplinary chronic pain clinics.
Baseline
(𝑛 = 808)
Six months
(𝑛 = 801)
Twelve months
(𝑛 = 744)
Total throughout the
one-year follow-up
(𝑛 = 744)
IPM and/or OTC
performed on-site
Yes 89 122 139 —
No 719 679 605 —
𝑛 % 𝑛 % 𝑛 % 𝑛 %
IPM
Nerve blocks 39 4.8 32 4.0 20 2.7 88 11.8
Viscosupplementation 18 2.2 1 0.1 1 0.1 16 2.2
Radiofrequency 13 1.6 11 1.4 5 0.7 28 3.8
Botulinum toxin 10 1.2 2 0.2 1 0.1 12 1.6
Epidural injections 9 1.1 9 1.1 1 0.1 17 2.3
Neurostimulation — — 1 0.1 — — 1 0.1
Total 89 11.0 56 7.0 28 3.8 162 21.8
OTP performed on-site
Acupuncture 33 4.1 20 2.5 12 1.6 52 7.0
Infusions 21 2.6 8 1.0 11 1.5 31 4.2
Mesotherapy 1 0.1 1 0.1 — — 2 0.3
Total 55 6.8 29 3.6 23 3.1 85 11.4
At the top of the table, in each row there is the cumulative number of patients who had interventional pain management and/or other therapeutic procedures
prescribed at multidisciplinary chronic pain clinics at each assessment time point. 푛, number of patients at each assessment time point. Furthermore, in each
row there are the number of patients (푛) and proportions of patients (%) that were prescribed interventional painmanagement or other therapeutic procedures
performed on-site atmultidisciplinary chronic pain clinics at each assessment time point and during the follow-up time. IPM, interventional painmanagement.
OTP, other therapeutic procedures.
nerve blocks were the most frequently prescribed at all time
points (39 patients at baseline, 32 patients at 6 months, 20
patients at 12 months, and 88 patients in total throughout
the one-year follow-up). On the contrary, botulinum toxin
and viscosupplementation were prescribed to a few patients
and almost exclusively at baseline. Neuromodulation by
neurostimulation was only prescribed to one patient at 6
months. OTP were also prescribed to a considerable number
of patients. Among them, acupuncture was prescribed to 52
patients throughout the study, followed by drug infusions to
31 patients.
Sociodemographic characteristics of all patients, patients
with IPM, and patients without IPM are described in Table 2.
It was observed that 17.2% of the patients followed in MCPC
had IPM prescribed, of which 71.9% were women and 28.1%
men. Moreover, age was significantly lower in patients with
IPM (54.6 (44.0–65.0) versus 59.7 (50.0–71.0) years, 𝑝 <
0.001). Elderly patients (over 75 years) were less frequently
prescribed IPM. Patients with IPM were mainly full- or part-
time workers while those without IPM were mostly retirees
(𝑝 < 0.001).
Table 3 shows pain clinical characteristics, at the inclusion
time in our study, among all patients, patients with IPM,
and patients without IPM. Almost 1/3 of the patients with
IPM had pain for over 10 years, while almost 90% of patients
with pain duration from 3 to 12 months did not have IPM
(𝑝 = 0.006). Patients in both groups referred to almost exclu-
sively continuous pain. Significant differences in pain inten-
sity could only be seen for pain at its worst (8.01 without IPM
versus 7.23 with IPM; 𝑝 = 0.003).The location of the pain was
heterogeneous and statistically significant differences were
found; in all patients that indicated pain in unspecified bones,
joints, andmuscles 92.1%were patients without IPM,whereas
among all cases of pain in inguinal and pelvic region 31.2%
are reported by patients with IPM (𝑝 = 0.047). Patients with
IPM had significantly lower pain interference score (𝑝 <
0001). Specifically, pain-related interference was inferior in
general ability (6.20 ± 3.26 versus 7.04 ± 2.71, 𝑝 = 0.015),
walking ability (5.76 ± 3.81 versus 6.67 ± 3.44, 𝑝 = 0.024),
normal work (6.09 ± 3.53 versus 7.26 ± 2.82, 𝑝 < 0.001),
relations with other people (3.17±3.64 versus 4.22±3.58, 𝑝 =
0.002), and enjoyment of life (4.18 ± 3.95 versus 5.55 ± 3.79,
𝑝 < 0.001). More than 57% of patients who had no pain
interference had invasive techniques for pain management,
while 88.1% of patients with severe interference did not had
IPM prescribed. In general health no differences were found.
Using the ICD 10 to classify patient’s pathologies, 34
diagnoses were obtained from all patients. The five most
prevalent diagnoses in patients with IPM were low back pain
(28 patients), chronic postoperative pain (16 patients), knee
pain (16 patients), pelvic and perineal pain (13 patients),
and low back with sciatica (11 patients). We only found five
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Table 2: Sociodemographic characteristics of all patients, chronic pain patients with interventional pain management, and chronic pain
patients without interventional pain management.
All †CP patients CP patients withoutIPM CP patients with IPM ∗𝑝
𝑛 % 𝑛 % 𝑛 % UF (%)
Gender
Male 265 32.8 226 33.8 39 28.1 14.7 0.199
Female 543 67.2 443 66.2 100 71.9 18.4
Total 808 100.0 669 100.0 139 100.0 17.2
Age
Median
(P25–P75)
60.0
(48.3–70.8)
59.7
(50.0–71.0)
54.6
(44.0–65.0) <0.001
Age categories
18–24 years 9 1.1 5 0.7 4 2.9 44.4
0.010
25–34 years 31 3.8 21 3.1 10 7.2 32.3
35–44 years 108 13.4 87 13.0 21 15.1 19.4
45–54 years 164 20.3 132 19.7 32 23.0 19.5
55–64 years 190 23.5 156 23.3 34 24.5 17.9
65–74 years 180 22.3 154 23.0 26 18.7 14.4
75 years or older 126 15.6 114 17.0 12 18.6 9.5
Total 808 100.0 669 100.0 139 100.0 17.2
Family household
Alone 84 10.4 69 10.3 15 10.8 17.9
0.121
With wife/husband or partner 317 39.2 262 39.2 55 39.6 17.4
With wife/husband or partner
and sons/daughters 244 30.2 192 28.7 52 37.4 21.3
With sons/daughters 62 7.7 54 8.1 8 5.8 12.9
In elderly care homes 2 0.2 2 0.3 — — —
Other 99 12.3 90 13.5 9 6.5 9.1
Total 808 100.0 669 100.0 139 100.0 17.2
Professional/occupational status
Full or part-time worker 242 30.0 180 26.9 62 44.6 25.6
<0.001
Student 6 0.7 5 0.7 1 0.7 16.7
Unemployed 101 12.5 84 12.6 17 12.2 16.8
House worker or domestic
worker 33 4.1 26 3.9 7 5.0 21.2
Retired or preretired 387 47.9 342 51.1 45 32.0 11.6
Other 39 4.8 32 4.8 7 5.0 17.9
Total 808 100.0 669 100.0 139 100.0 17.2
Education level
No education 24 3.0 24 4.1 — — —
0.195
1–4 years (basic 1st cycle) 401 49.8 330 56.4 71 51.1 17.7
5–9 years (basic 2nd and 3rd
cycles) 189 23.4 156 26.7 33 23.7 17.5
10–12 years (secondary) 85 10.5 66 11.3 19 13.7 22.4
More than 12 years (higher) 86 10.7 74 12.6 12 8.6 14.0
Other 21 2.6 17 2.6 4 2.9 19.0
Total 806 100.0 667 100.0 139 100.0 17.2
Each row of the table includes absolute (푛) and relative (%) frequencies of each characteristic and the utilization frequency (%) of interventional pain
management by category (UF). Highlighted in bold are statistically significant results, at a 0.05 significance level. CP, chronic pain. IPM, interventional
pain management. P25–P75, 25th percentile and 75th percentile (representing the interquartile range).∗푝 value for statistical hypothesis tests comparing the
subsample of CP subjects with IPM to CP subjects without IPM. Chi-square test or Fisher’s exact test for categorical variables and Mann–Whitney test for
numerical variables were used. †Chronic pain was defined, using the IASP standard definition, as pain present with duration ≥3 months.
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Table 3: Clinical characteristics of all patients, chronic pain patients with interventional painmanagement, and chronic pain patients without
interventional pain management.
Clinical characteristics of pain All †CP patients CP patients withoutIPM CP patients with IPM
∗𝑝
𝑛 % 𝑛 % 𝑛 % UF (%)
Duration (categorized)
≤3 months–≤1 year 218 27.3 196 29.7 22 15.8 10.1
0.006
<1-≤2 years 110 13.8 87 13.2 23 16.5 20.9
<2–≤5 years 157 19.6 128 19.4 29 20.9 18.5
<5–≤10 years 123 15.4 103 15.6 20 14.4 16.3
>10 years 191 23.9 146 22.1 45 32.4 23.6
Total 799 100.0 660 100.0 139 100.0 17.4
‡Persistence pattern
Continuous 754 93.4 626 93.7 128 92.1 17.0 0.455
Discontinuous 53 6.6 42 6.3 11 7.9 20.8
Total 807 100.0 668 100.0 139 100.0 17.2
Mean (SD) Mean (SD) Mean (SD)
Intensity
Pain on average (0–10 NRS) 5.96 (2.13) 6.00 (2.01) 5.77 (2.50) 0.641
Pain at its least (0–10 NRS) 3.63 (2.50) 3.63 (2.44) 3.63 (2.79) 0.759
Pain at its worst (0–10 NRS) 7.88 (2.11) 8.01 (1.98) 7.23 (2.61) 0.003
Pain right now (0–10 NRS) 4.83 (2.99) 4.88 (2.94) 4.58 (3.23) 0.304
𝑛 % 𝑛 % 𝑛 % UF (%)
No pain 14 1.8 6 0.9 8 6.2 57.1
<0.001
§Mild 229 29.4 181 27.8 48 37.2 21.0
§Moderate 244 31.3 215 33.0 29 22.5 11.9
§Severe 293 37.6 249 38.2 44 34.1 15.0
Total 780 100.0 651 100.0 129 100.0 16.5
||Location
Lower limb 742 34.4 590 33.7 152 38.7 20.5
Dorsum and lower back 414 19.3 343 19.6 71 18.1 17.1
Upper limb 363 16.9 288 16.4 75 19.1 20.7
Cervical and facial region 261 12.1 224 12.8 37 9.4 14.2 0.047
Bones/joints/muscles- unspecified 89 4.1 82 4.7 7 2.3 7.9
Abdominal and anterior thoracic region 87 4.0 78 4.4 9 6.1 10.3
Inguinal and pelvic region 77 3.6 53 3.0 24 4.6 31.2
Other 115 5.6 97 5.5 18 4.6 15.7
Total 2150 100.0 1757 100.2 393 100.0 18.3
Mean (SD) Mean (SD) Mean (SD)
Pain-related interference
General activity 6.90 (2.82) 7.04 (2.71) 6.20 (3.26) 0.015
Mood 6.25 (3.28) 6.37 (3.21) 5.64 (3.58) 0.054
Walking ability 6.52 (3.51) 6.67 (3.44) 5.76 (3.81) 0.024
¶Normal work 7.06 (2.98) 7.26 (2.82) 6.09 (3.53) <0.001
Relations with other people 4.05 (3.60) 4.22 (3.58) 3.17 (3.64) 0.002
Sleep 5.64 (3.80) 5.72 (3.81) 5.20 (3.74) 0.087
Enjoyment of life 5.33 (3.84) 5.55 (3.79) 4.18 (3.95) <0.001
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Table 3: Continued.
Clinical characteristics of pain All †CP patients CP patients withoutIPM CP patients with IPM
∗𝑝
𝑛 % 𝑛 % 𝑛 % UF (%)
mInterference
No interference 14 1.8 6 0.9 8 6.3 57.1
<0.001Mild 229 29.4 180 27.6 49 38.3 21.4
Moderate 244 31.3 208 31.9 36 28.1 14.8
Severe 293 37.6 258 39.6 35 27.3 11.9
Total 780 100.0 652 100.0 128 100.0 16.4
General health
Excellent 13 1.6 11 1.7 2 1.4 15.4
Very good 15 1.9 12 1.8 3 2.2 20.0
Good 117 14.6 94 14.1 23 16.5 19.7 0.082
Fair 342 42.5 271 40.8 71 51.1 20.8
Poor 317 39.4 277 41.7 40 28.8 12.6
Total 804 100.0 665 100.0 139 100.0 17.3
Each row of the table includes the absolute (푛) and relative (%) frequencies of each characteristic, the utilization frequency (%) of interventional pain
management by category (UF (%)), and in some cases the mean and standard deviation (SD). Highlighted in bold are statistically significant results, at a
0.05 significance level. CP, chronic pain. IPM, interventional pain management. SD, standard deviation. ∗푝 value for statistical hypothesis tests comparing the
subsample of CP subjects with IPM to CP subjects without IPM. Chi-square test or Fisher’s exact test for categorical variables and Mann–Whitney test for
numerical variables were used. †Chronic pain was defined, using the IASP standard definition, as pain present with duration ≥3 months. ‡Persistence pattern:
continuous—pain present every day/ always; discontinuous—recurrent (pain present once to several times/ week); and sporadic (pain present less than once to
several times/month). §Pain intensity score was categorized taking into account the Serling classification: mild (1–4), moderate (5-6), and severe pain intensity
(7–10). ||Multiple pain locations were recorded for each patient. ¶Including both work outside the home and housework. mPain interference was categorized as
mild (1–4), moderate (5-6), and severe pain interference (7–10).
significant differences between patients with and without
IPM in what concerns the diagnosis. IPM was only used in
2.8% of patients with fibromyalgia (𝑝 = 0.013) and 4.2% of
patients with cancer pain (𝑝 < 0.001), while it was used in
36.7%of patientswith lowback painwith sciatica (𝑝 = 0.011),
41% of patients with knee (𝑝 < 0.001) pain, and 46.4% of
patients with pelvic or perineal pain (𝑝 < 0.001) (Supplement
2).
Throughout the study 420 treatments were prescribed as
seen in Table 4. The most prescribed IPM in all assessment
time points was nerve blocks. In one-year follow-up nerve
blocks were 108 times prescribed followed by radiofrequency
(31 prescriptions) and viscosupplementation (22 prescrip-
tions). The botulinum toxin and viscosupplementation pre-
scriptions were scarce and occurred almost exclusively at
baseline. The most prescribed OTP performed on-site at
MCPC at baseline were infusions (43 prescriptions) and at 6
and 12 months acupuncture (73 and 45 prescriptions, resp.).
The five most frequent diagnoses of patients that were
prescribed each of the IPM and/or OTP are shown in
Table 5. IPM was not exclusive to patients with a specific
diagnosis. Nerve blocks, epidural, and radiofrequency were
extensively used in several diagnoses, and the same occurred
with acupuncture. Botulin toxin was prescribed to 69.2% of
patients with pelvic and perineal pain; viscosupplementation
was prescribed to 68.4% of patients diagnosed with knee
pain. Considering OTP performed on-site at MCPC, drug
infusions were prescribed to 57.9% of patients with cancer
pain.
There was large heterogeneity in the type of treatments
and prescription frequency in each MCPC. It is noted that
there are techniques only prescribed in some MCPC, such as
viscosupplementation, radiofrequency, botulinum toxin, and
neurostimulation. One MCPC had only OTP performed on-
site (Supplement 3).
4. Discussion
There are very few studies focused on IPMutilization patterns
in multidisciplinary CP clinics [17, 24]. To our best knowl-
edge, this is the first study focused on this issue in Portugal
and one of the very few elsewhere.
We found that nerve blocks were the most frequent IPM
prescribed in MCPC; with a total of 420 IPM or OTP pre-
scribed during the one-year follow-up. A total of 139 patients
(17.2%) in our cohort received IPM for their CPmanagement.
Of those, almost 32.4% had pain for over 10 years and 92.1%
of these reported a continuous pain pattern. There was a
diversity of IPM prescribed in the participating MCPC, and
botulinum toxin, viscosupplementation, neurostimulation,
and radiofrequency were only available in very few centers.
In our cohort there is a higher prevalence of women with CP
which is in accordance with the available literature [10, 20,
58], and average pain intensity was approximately 6 in a 0–10
numerical rating scale.
In general, the success of these techniques is partly
dependent on the experience and skill of the provider.
There is controversy over the evidence that supports these
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Table 4: Prescriptions and rate of prescription of interventional pain management and other therapeutic procedures performed on-site at
multidisciplinary chronic pain clinics at baseline, six months, and twelve months and during the whole follow-up period.
Baseline
(𝑛𝑡 = 808)
Six months
(𝑛𝑡 = 801)
Twelve months
(𝑛𝑡 = 744)
Total throughout the
one-year follow-up
(𝑛𝑡 = 744)
𝑛 Rate 𝑛 Rate 𝑛 Rate 𝑛 Rate
Interventional pain
management
Nerve blocks 41 5.1 51 6.4 37 5.0 108 14.5
Viscosupplementation 19 2.4 6 0.7 4 0.5 22 3.0
Radiofrequency 12 1.5 16 2.0 5 0.7 31 4.2
Botulinum toxin 10 1.2 2 0.2 3 0.4 14 1.9
Epidural injections 9 1.1 11 1.4 2 0.3 19 2.6
Neurostimulation — — 1 0.1 — — 1 0.1
Total 91 11.3 87 10.9 51 6.9 195 26.2
OTP performed on-site
Infusions 43 5.3 38 4.7 25 3.4 95 12.8
Acupuncture 38 4.7 73 9.1 45 6.0 128 17.2
Mesotherapy 1 0.1 1 0.1 — — 2 0.3
Total 82 10.1 199 14.0 70 9.4 225 30.2
Each row of the table includes the number of interventional pain management or other therapeutic procedures performed on-site at multidisciplinary chronic
pain clinics at each assessment time point and during the follow-up time (푛), the average number of prescriptions per 100 patients at each assessment time
point (rate). 푛푡, number of patients at each assessment time point. OTP, other therapeutic procedures.
techniques [16], as there is no sufficient data to ascertain the
efficacy of some procedures. In some cases, pain relief is only
observed during a short period and does not essentially con-
vert into improved function and reduced work absenteeism
[59]. Moreover, there is a risk of potential complications
associated, but most are transient and often subclinical [30].
IPM techniques have been used for a long time as a last option
for patients when all other conservative approaches have
failed. Therefore, it is understandable that patients to whom
they are actuality prescribed have a much longer reported
pain duration [59].
In the present study, IPM were prescribed mainly to
patients that did not report significant interference of pain, as
measured by the functional interference scale of theBrief Pain
Inventory, while the vast majority of patients that reported
severe interference were not prescribed IPM. The reasons
for these unexpected results are not clear at present, and
one can only speculate that patients with severe interference
suffered from conditions and/or had a health status (e.g.,
comorbidities) less likely to be treated by IPM, but additional
data is required to investigate this issue.
Among the great variety of IPM used inmultidisciplinary
pain management [14, 25], six techniques plus three OTP
performed on-site at MCPC were prescribed in the course of
our study.
Nerve blocks, the most frequently prescribed technique
in the present study (88 patients), consist in anesthetics
delivered to visceral and peripheral nerves in order to
interrupt nociceptive input at the source of pain [16, 28].
This procedure may be understood, especially by patients, as
curative, but similarly to other IPM techniques, that is not the
case. However, it can be very useful, for instance, to alleviate
pain and allow patient to take part in their physical therapy
[30].
Viscosupplementation consists of intra-articular injec-
tion of hyaluronic acid derivatives. It is one of the more used
local treatments for osteoarthritis along with corticosteroid
injection. It has been used mainly in knee joint, where it
showsmoderate and significant pain reduction and increased
function [32], but a recent meta-analysis provided no evi-
dence that the effect remains longer than six months [31].
Radiofrequency denervation consists in nerve ablation
using heat generated by a radiofrequency current [38]. Facet
joints radiofrequency is one of themost prevalent indications
for its use with high rates of clinical improvement. However,
these effects have also a limited temporal efficacy [25, 39].
Botulinum toxin injections as well as acupuncture and
dry needling techniques are effective options for myofascial
pain, namely, trigger point’s deactivation [36, 38]. However
there is no clear evidence about long-term effectiveness of
botulinum toxin treatment [35].
Epidural injectionwas primarily recommended for radic-
ular pain from a herniated disc but could also be performed
in patients with spinal stenosis and other low back pain
conditions [25, 26]. Fair evidence of moderate benefit versus
placebo injection for short-term low back pain relief was
found [27], and even when compared with other pharmaco-
logical treatment, epidural injection may be better in some
outcomes, but the differences are transient and modest [28].
In fact, epidural steroid injections are the most commonly
performed procedure in USA, differing from what we have
found in our study, yet evidence is controversial and incon-
clusive as to their long-term effectiveness [25, 28, 29]. The
potential complications associated with neuraxial techniques
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Table 5: Characterization of interventional pain management and other therapeutic procedures performed on-site at multidisciplinary
chronic pain clinics by the five main diagnoses.
Interventional pain
management ICD-10 diagnostic classification
Nerve blocks Low back pain Chronicpostoperative pain
Low back pain with
sciatica Shoulder pain Cervicalgia
np (%) 23 (25.7) 14 (15.4) 9 (9.9) 5 (5.5) 5 (5.5)
ni (%) 32 (20.9) 22 (14.4) 12 (7.8) 7 (4.6) 5 (3.3)
Viscosupplementation Knee pain
Unspecified
osteoarthritis,
unspecified site
Chronic
postoperative pain
Pain in unspecified
joint
Low back pain with
sciatica
np (%) 13 (68.4) 3 (15.8) 1 (5.3) 1 (5.3) 1 (5.3)
ni (%) 22 (75.9) 3 (10.3) 1 (3.4) 2 (6.9) 1 (3.4)
Botulinum toxin Pelvic and perinealpain
Central pain
syndrome
Chronic
postprocedural pain Cancer pain
Lower abdominal
pain, unspecified
np (%) 9 (69.2) 1 (7.7) 1 (7.7) 1 (7.7) 1 (7.7)
ni (%) 11 (73.3) 1 (6.7) 1 (6.7) 1 (6.7) 1 (6.7)
Radiofrequency Low back pain Low back pain withsciatica Shoulder pain Knee pain
Other hereditary and
idiopathic
neuropathies
np (%) 7 (25.0) 5 (17.9) 3 (10.7) 3 (10.7) 2 (7.1)
ni (%) 9 (27.3) 5 (15.2) 3 (9.1) 3 (9.1) 2 (6.1)
Epidural injections Low back pain Low back pain withsciatica Hip pain
Chronic
postoperative pain
Radiculopathy,
lumbar region
np (%) 5 (26.3) 4 (21.1) 2 (10.5) 2 (10.5) 2 (10.5)
ni (%) 5 (22.7) 4 (18.2) 2 (9.1) 2 (9.1) 3 (16.6)
Neurostimulation Chronicpostoperative pain
np (%) 1 (100.0)
ni (%) 1 (100.0)
OTP performed on-site ICD-10 diagnostic classification
Infusions Cancer pain Disorders oftrigeminal nerve
Chronic
postoperative pain
Radiculopathy,
lumbar region Cervicalgia
np (%) 22 (57.9) 4 (10.5) 3 (7.9) 2 (5.3) 2 (5.3)
ni (%) 37 (45.1) 26 (31.7) 5 (6.1) 13 (15.9) 13 (15.9)
Acupuncture Low back pain Cervicalgia Myalgia Pain in unspecifiedjoint Fibromyalgia
np (%) 15 (23.1) 11 (16.9) 6 (9.2) 5 (7.7) 5 (7.7)
ni (%) 49 (30.4) 12 (7.5) 27 (16.8) 5 (3.1) 22 (13.7)
Mesotherapy Low back pain
Unspecified
mononeuropathy of
lower limb
np (%) 1 (50.0) 1 (50.0)
ni (%) 1 (50.0) 1 (50.0)
Each row of the table includes the number of patients and percentage (%) that were prescribed interventional treatments or other therapeutic procedures
performedon-site atmultidisciplinary chronic pain clinics (np) and the number andpercentage (%) of prescribed interventional treatments or other therapeutic
procedures performed on-site at multidisciplinary chronic pain clinics (ni). ICD, International Statistical Classification of Diseases and Related Health
Problems. OTP, other therapeutic procedures.
performance may explain the low prevalence reported on its
use.
Neuromodulation is used in some Portuguese MCPC.
However, during the recruitment period of our study there
was only one patient who was referred to this treatment
[33]. Spinal cord stimulation has formal indication in CP
conditions such as failed back surgery, complex regional
pain syndrome, peripheral vascular diseases (Buerger disease,
Raynaud syndrome, and limb ischemia I/II), and refractory
angina pectoris [34].
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Taking into consideration OTP performed on-site, pre-
scribed in the MCPC, acupuncture was the most frequently
prescribed. Some evidence supports acupuncture effective-
ness for chronic low back pain treatment [41], fibromyalgia
[42], and neck pain treatment [43]. It is increasingly pre-
scribed [40], but the lack of strong studies that clearly prove
its effectiveness has delayed its global recognition [44–46].
Pain is a common symptom in cancer patients. In spite of
advances in pain management, effective pain control remains
an ongoing challenge, despite high doses of opioids [47].
Drugs infusions can be used safely and should be considered
to manage cancer neuropathic pain [47, 48]. Trigeminal neu-
ralgia is the most common neuralgia in which intravenous
infusion of lidocaine may be a therapeutic option when other
treatments are ineffective [49].Thus further investigationwill
be needed to evaluate clinical significance of infusion therapy
[48].
The present findings clarify which and in what extent
IPM and OTP performed on-site at MCPC are being pre-
scribed.This study has several strengths, namely, inclusion of
several MCPC, a well-structured and detailed questionnaire,
telephonic interviews performed systematically, a restricted
and trained team, a large sample, and a 12-month follow-
up period. The data presented are unique and to the best
of our knowledge there are no similar data in other MCPC
that describe their current clinical practice and are useful for
comparison and benchmarking.
We have a comprehensive and systematic description of
IPM and OTP performed on-site, prescribed, and actually
used in MCPC, constituting the clear added value of our
study. However, some IPM can be performed for therapeutic
or diagnostic purposes and this has not been differentiated
in the present study. Further ongoing research will provide
data on the evaluation of real-world effectiveness andpatient’s
reported satisfaction by type and timing of techniques per-
formed.
5. Conclusions
In Portugal IPM is available in most MCPC, but with marked
diversity in the types of techniques and clinical indications.
IPM is still seldom prescribed, with only 17.2% of patients
having IPM as part of their management. Future studies
focused on patient’s reported effectiveness and satisfaction
are needed.
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